University of Queensland & CSL developed COVID-19 vaccine candidate (V451) , using their patented “molecular clamp” vaccine platform has been abandoned after trial participants returned false positive HIV test results.
CSL also said participants were told before the trial started that antibodies in the vaccine could interfere with certain HIV diagnostic tests. But it said there was no possibility the vaccine caused infection, and routine follow-up tests confirmed no HIV virus was present. The statement said that in order for the vaccine to be released, it would require "significant changes" to HIV testing procedures.
UQ vaccine co-lead Professor Paul Young said fixing the vaccine would have set back development by another year.
CSL also said participants were told before the trial started that antibodies in the vaccine could interfere with certain HIV diagnostic tests. But it said there was no possibility the vaccine caused infection, and routine follow-up tests confirmed no HIV virus was present. The statement said that in order for the vaccine to be released, it would require "significant changes" to HIV testing procedures.
UQ vaccine co-lead Professor Paul Young said fixing the vaccine would have set back development by another year.
